Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine and Cisplatin for Resectable Pancreatic Head Cancer
NCT00490360Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Zurich. Primary endpoint: Resectability rate after restaging. Started Oct 2001; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00490360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490360.